Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 6/20 | 0.62 |
| ▸ | PLD2 | O14939 | 4/20 | 0.46 |
| ▸ | PLD1 | Q13393 | 4/20 | 0.46 |
| ▸ | CCR2 | P41597 | 8/20 | 0.45 |
| ▸ | TACR1 | P25103 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631107 | 0.97 | TACR3 (0.59) | TACR3PLD2PLD1CCR2TACR1 | |
| SCHEMBL632137 | 0.96 | TACR3 (0.68) | TACR3PLD2PLD1CCR2TACR1 | |
| SCHEMBL630946 | 0.95 | TACR3 (0.57) | TACR3PLD2PLD1CCR2TACR1 | |
| SCHEMBL632868 | 0.94 | TACR3 (0.55) | TACR3PLD2PLD1CCR2TACR1 | |
| SCHEMBL632869 | 0.94 | TACR3 (0.55) | TACR3PLD2PLD1CCR2TACR1 | |
| SCHEMBL633512 | 0.93 | TACR3 (0.56) | TACR3PLD2PLD1CCR2TACR1 | |
| SCHEMBL631234 | 0.93 | TACR3 (0.72) | TACR3PLD2PLD1CCR2TACR1 | |
| SCHEMBL632866 | 0.91 | TACR3 (0.53) | TACR3PLD2PLD1CCR2TACR1 | |
| SCHEMBL632867 | 0.91 | TACR3 (0.53) | TACR3PLD2PLD1CCR2TACR1 | |
| SCHEMBL631934 | 0.91 | TACR3 (0.58) | TACR3PLD2PLD1CCR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099806-B1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | claimed |
| EP-2099806-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2009-09-16 | — | — | EP | claimed |
| US-7470684-B2 | Spiropiperidine derivatives as NK3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-12-30 | — | — | US | claimed |
| US-20080176839-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-24 | — | — | US | claimed |
| WO-2008081012-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | WO | claimed |
| EP-2099806-B1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | disclosed |
| CN-101622259-B | spiropiperidine derivatives as NK3 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-01 | — | — | CN | disclosed |
| EP-2099806-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-7470684-B2 | Spiropiperidine derivatives as NK3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470684-B2 | Spiropiperidine derivatives as NK3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470684-B2 | Spiropiperidine derivatives as NK3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080176839-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-24 | — | — | US | disclosed |
| US-20080176839-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-24 | — | — | US | disclosed |
| US-20080176839-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-24 | — | — | US | disclosed |
| WO-2008081012-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176839-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | ADRB3, KCNK3, KCND3 | TACR3 28/4885PLD2 1931/4885PLD1 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.